[Recent progress in biological therapies for cancer].
After approval of national health insurance for non-specific immunomodulation such as OK-432 (1978) and PSK (1980), lentinan, SPG, bestatin and dried BCG vaccine have been tried. Including cytokines such as IL-2, IL-12, IFN, TNF or monoclonal antibodies, they have been widely used as biological response modifiers (BRM). Progress in BRM therapy may be broken down into the first 10 years as development, the next 10 years as disappointment and the most recent 5 years as dream-like progress owing to molecular biological techniques. An interdisciplinary approach has been taken by the Japanese Research Society for Surgical Cancer Immunology, founded in 1980, and the Japanese Society of BRM founded in 1988. Many investigations have been performed on issues such as the clinical evaluation or criteria for responder cases, host immunocompetency, post-operative adjuvant immuno-chemotherapy, locoregional immunotherapy, cytokine therapy, adoptive immunotherapy, and tumor specific immunotherapy. Attention has also focused on malignant tumor injury, surgical stress, the advantages or disadvantages of splenectomy, and discussions of the current status and future prospects in the next century for new BRM therapy.
Saji
S
S
Second Dept. of Surgery, Gifu University School of Medicine.
Sugiyama
Y
Y
Kunieda
K
K
Umemoto
T
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D007912:Lentinan / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use; D011509:Proteoglycans / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D007155:Immunologic Factors; D011509:Proteoglycans; D007912:Lentinan; D010844:Picibanil; C010770:polysaccharide-K; D007372:Interferons